AbbVie had its Relative Strength (RS) Rating upgraded from 68 to 72 Monday — a welcome improvement, but still short of the 80 or better score you prefer to see.
This proprietary rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research shows that the best-performing stocks typically have an RS Rating north of 80 in the early stages of their moves. See if AbbVie can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
AbbVie is trying to complete a flat base with a 199.95 entry. See if it can break out in volume at least 40% higher than normal.
While earnings growth declined last quarter from -6% to -9%, revenue rose 4%, up from 1% in the previous report. The company is expected to report its latest numbers on or around Oct. 30.
AbbVie earns the No. 7 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Novartis ADR and Bristol Myers Squibb are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
